This could potentially be exploited by new treatment regimens that reduce cancer treatment side-effects, such as combination of hyperthermia with new classes of indirect double-strand break inducing agents, like PARP-inhibitors [12, 13]. This evidence concerns the gene PARP1 and cancer.